Bio-Rad Laboratories, Inc. (BIO) Stock Analysis
Score BGrowth · Grade C · Bearish
$280.44
$311.41
+11.0%
9/10
C
Growth
Investment Thesis
Price is above modeled value range. Quality supports holding but not attractive for new positions.
Appears undervalued but quality concerns keep the score lower.
For New Investors
Price above modeled value range
For Current Holders
Quantitative score: neutral
Buy if
- Price drops 15-20% (improves asymmetry)
- Bull scenario catalysts materialize
- Market-wide correction creates opportunity
Sell if
- Bear scenario triggers occur
- Quality metrics deteriorate (ROIC declining)
- Better alternatives emerge
Valuation
Fair Value estimate: $311.41 (+11.0%). Slightly undervalued.
FCF DCF Model
$263.38
EV/EBITDA
$364.57
Blended Fair Value
$311.41
Confidence
High
Methods
FCF 2-Stage DCF (turnaround), EV/EBITDA (turnaround), Revenue Multiple (turnaround)
Quality Analysis
68/120 points
Investable
ROE (3Y Avg)
-8.4%
ROIC-WACC Spread
-7.0%
D/E Ratio
0.2x
Current Ratio
5.6x
Interest Coverage
6x
FCF Positive Years
3/3
Quality Flags
- Low ROE: -8.4% (need >15%, got 0/20 pts)
- ROIC spread: -7.0pp (got 0/25 pts)
- Leverage: D/E 0.2x (13/15 pts)
Market Sentiment
Wall Street Consensus
$320.00
+14.1% Upside
5 analysts
Range: $290.00 — $335.00
Rating: Hold
Our model aligns with Wall Street consensus.
Trend & Technical
Price ($280.77) is 4.0% below SMA 200 ($292.44). Bearish trend. Caution on entry.
Tech Score 51/100 — Neutral technical picture. Mixed signals across indicators.
Risk & Reward
Asymmetry Ratio
10.00:1
Expected Return
+60.9%
Bull Upside
+145.2%
Bear Downside
-10.0%
Excellent asymmetry: >3:1 ratio. Upside significantly outweighs downside.
Verdict: Very Favorable
Scenario Analysis
Bear
Base
Bull
Buy Zone & Action Plan
See exact entry zones, stop-loss levels, and a personalized action plan.
AI Executive Summary
Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.
Technical Analysis
RSI, MACD, moving averages, trend signals, and momentum indicators.
Ask AI about this stock
Chat with our AI analyst to ask questions about valuation, risks, or comparisons.
Frequently Asked Questions
What is the fair value of BIO?
Based on our multi-method conviction analysis, the estimated fair value of Bio-Rad Laboratories, Inc. (BIO) is $311.41. This is calculated by blending FCF 2-Stage DCF (turnaround), EV/EBITDA (turnaround), Revenue Multiple (turnaround) and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is high.
Is BIO a buy, sell, or hold?
BIO currently has a HOLD rating with a conviction score of 9/10. Price is above modeled value range. Quality supports holding but not attractive for new positions. Price above modeled value range.
Is BIO a high-quality stock?
Bio-Rad Laboratories, Inc. has a quality grade of C (68/120 points), rated as Investable. Key metrics include ROE of -8.4%, ROIC-WACC spread of -7.0%, and D/E ratio of 0.2x.
What type of stock is BIO?
BIO is classified as a "growth" in our framework. High P/E: 46.8x, Low dividend (reinvesting): 0.0%, Mature growth: 0.2%, Market-like beta: 1.06, Consistent FCF: 3/3 years positive
What do Wall Street analysts say about BIO?
5 Wall Street analysts have a consensus price target of $320.00 for BIO, representing +14.1% upside. Targets range from $290.00 to $335.00. The consensus recommendation is "Hold". Our model aligns with Wall Street consensus.
What are the risks of investing in BIO?
The risk/reward asymmetry ratio for BIO is 10.00:1, rated as Very Favorable. Excellent asymmetry: >3:1 ratio. Upside significantly outweighs downside. The expected return is +60.9%, with bull case upside of +145.2% and bear case downside of -10.0%.
What is the current trend for BIO?
BIO is in a bearish trend. Price ($280.77) is 4.0% below SMA 200 ($292.44). Bearish trend. Caution on entry. The technical score is 51/100.
Related Stock Analyses
Best Stocks to Buy
Get the complete analysis
Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.
Last updated: May 19, 2026 · Framework version 3.7
This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.